<DOC>
	<DOCNO>NCT02751931</DOCNO>
	<brief_summary>A study evaluate efficacy , safety tolerability , pharmacokinetics mirabegron multiple-dose administration pediatric population .</brief_summary>
	<brief_title>Open-label Phase 3 Study With Mirabegron Children From 3 Less Than 18 Years Age With Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description>This phase 3 , open-label , baseline-controlled , multicenter study . The study consist 3 period : Pretreatment period : maximum 28 day baseline , include screening , washout ( applicable ) baseline . Efficacy treatment period : beginning day baseline continue visit 8/week 24 . Long-term safety period : begin visit 8/week 24 continue visit 10/week 52 ( end study [ EOS ] ) , end treatment ( EOT ) .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject body weight great equal 11 kg . Subject suffers NDO confirm urodynamic investigation baseline . The diagnosis NDO must confirm presence least 1 involuntary detrusor contraction &gt; 15 cm H2O baseline detrusor pressure , and/or decrease compliance lead increase baseline detrusor pressure &gt; 20 cm H2O . Subject use CIC least 4 week prior visit 1/screening . Subject current indication drug therapy manage NDO . Subject able take study drug accordance protocol Subject know genitourinary condition ( NDO ) may cause overactive contraction incontinence kidney/bladder stone another persistent urinary tract pathology may cause symptom . Subject one follow gastrointestinal problem : partial complete obstruction , decrease motility paralytic ileus , subject risk gastric retention . Subject urinary indwelling catheter within 4 week prior visit 1/screening . Subject surgically treat underactive urethral sphincter Subject vesicoureteral reflux grade 3 5 . Subject undergone bladder augmentation surgery . Subject receive electrostimulation therapy , start within 30 day visit 1/screening expect start study period . Subjects establish regimen may remain duration study . Subject suffers symptomatic urinary tract infection ( UTI ) baseline ( symptomatic define pain , fever , hematuria , new onset foulsmelling urine ) . If present visit 1/screening diagnose visit 1/screening visit 3/baseline , UTI treat successfully ( clinical recovery ) prior baseline . If symptomatic UTI present baseline , baseline assessment allow postponed maximum 7 day UTI successfully treat ( clinical recovery ) . Subject ( mean ) rest pulse rate &gt; 99th percentile [ Fleming et al , 2011 ] . Subject establish hypertension systolic diastolic blood pressure great 99th percentile normal range determine sex , age height , plus 5mmHg [ NIH 2005 ] . Subject risk QT prolongation ( e.g. , hypokalemia , long QT syndrome [ LQTS ] ; family history LQTS , exerciseinduced syncope ) . Subject severe renal impairment ( eGFR accord Larsson equation &lt; 30 mL/min ) . Subject 's aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great equal 2 time upper limit normal ( ULN ) total bilirubin ( TBL ) great equal 1.5 time ULN accord age sex . Subject history presence malignancy prior visit 1/screening . Subject know suspected hypersensitivity mirabegron , excipients use current formulation previous severe hypersensitivity drug . Subject participate another clinical trial ( and/or take investigational drug within 30 day ( 5 halflives drug , limit set national law , whichever long ) prior visit 1/screening . Subject use follow prohibit medication ( start washout ) : Any medication , study drug use , management NDO ; Any drug sensitive CYP2D6 substrates narrow therapeutic index sensitive Pglycoprotein ( Pgp ) substrates Any strong CYP3A4 inhibitor subject mild moderate renal impairment ( eGFR 30 89 mL/min ) . Subject administer intravesical botulinum toxin ; except give &gt; 4 month prior visit 1/screening subject experience symptom comparable exist prior botulinum toxin injection .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>Urodynamics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Neurogenic Detrusor Overactivity</keyword>
</DOC>